Lacutamab
As of the edition of 20 October 2026, Lacutamab is an antibody: in active development; acts on KIR3DL2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2021
- Kind
- Antibody
- Registered trials
- 4, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KIR3DL2 | Killer cell immunoglobulin-like receptor 3DL2 | P43630 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innate Pharma | Lead sponsor of trials | 2015 to now |